Company intelligence / Profile preview

Immunicon

Huntingdon Valley, Pennsylvania, United Statessec.gov ↗

Ownership: Private
Employees: ~140
Development stage: Commercial

Overview

Immunicon developed the CellSearch System—the first FDA-cleared diagnostic test for automated detection and enumeration of circulating tumor cells in blood. The system was cleared for prognosis and monitoring of metastatic breast, colorectal, and prostate cancers. The company also developed advanced FISH DNA probe technologies. Its platforms were used both clinically and in pharmaceutical research collaborations[1][3][4].

Therapeutic areas: OncologyCardiovascular
Modalities: Cell-based diagnosticsMolecular diagnostics
Industry: Pathology

Partnerships

Veridex LLC / Johnson & Johnson – strategic development/commercialization partnership since 2000; eventual acquirerEisai Co., Ltd. – biomarker development collaboration for targeted therapy monitoring

Beyond the preview

Go deeper on Immunicon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunicon.

Explore the full profile